Results from five new studies on Genomic Health's Oncotype DX breast cancer test anno
 

Genomic Health, Inc. today announced results from five new studies on its Oncotype DX® breast cancer test, a multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit and recurrence risk for patients with early-stage breast cancer.

More...

Re: Results from five new studies on Genomic Health's Oncotype DX breast cancer test
 

Nice. I remember bringing this up to oncs at Mayo in '05. Thought I was crazy.

Re: Results from five new studies on Genomic Health's Oncotype DX breast cancer test
 

Rich,
I understand that this test is very expensive. Many insurance companies don't cover.

Regards
Joe

Re: Results from five new studies on Genomic Health's Oncotype DX breast cancer test
 

Yeah..well...would have gladly paid out of pocket to avoid recurrence. Joe, you would be amazed to see (in the session notes) how they thought I was paranoid over the her2 issue. I even brought up the her2 site and they said it was just a bunch of unrepresentative extreme cases.

Re: Results from five new studies on Genomic Health's Oncotype DX breast cancer test
 

Rich,

A lot of docs that use it will not use it for Her2+ patients, because all of the results come back as high risk. I'm not sure it would have provided you any additional information to the pathology.

Hopeful

Re: Results from five new studies on Genomic Health's Oncotype DX breast cancer test
 

Her pathology was and has been borderline. At the time, they judged things strictly by size of tumor. You could see the change coming. And perhaps this tool was a harbinger.